Alcami acquired by capital groups; Wheeler Bio starts at new manufacturing site in Oklahoma – Endpoints News



Two investment groups have joined forces to buy CDMO Alcami.

Global Healthcare Opportunities, also known as GHO Capital, and The Vista Group have partnered to acquire a majority stake in Alcami Corporation from funds associated with two other investment groups, Ampersand Capital Partners and Madison Dearborn Partners. Financial details of the deal were not disclosed to Terminal News.

Mike Mortimer, the managing partner and founder of GHO Capital, said in an email to Endpoints, the company has extensive experience in the CDMO space and is monitoring Alcami’s growth.

Mortimer said in the email:

We have built a very strong relationship with Alcami’s management team during this time and through our deep healthcare market expertise and reputation for helping companies expand their capabilities and geographic reach. Alcami represents a unique opportunity to acquire a rapidly growing CDMO with complementary capabilities in attractive markets. GHO Capital has the expertise and knowledge to help the company advance its compelling international growth plans.

The deal is expected to close by the end of the year, with GHO Capital and The Vistria Group securing a 50/50 majority stake in Alcami from funds affiliated with MDP and Ampersand. Ampersand and Alcami plan to reinvest equity in connection with the acquisition.

Mortimer also pointed out that Alcami is poised to have a high return on investment totaling $140 million and positions it for future growth.

Wheeler Bio begins construction of manufacturing plant in downtown Oklahoma City

CDMO Wheeler Bio has embarked on a new construction project in Oklahoma.

The project will be a 35,000 square foot drug substance manufacturing facility to manufacture materials for clinical trials. The site will be located in the Ziggurat building in downtown Oklahoma City and will be part of the city’s biotech hub. The site will include production suites, a quality control laboratory, offices and warehouse space.

Jesse McCool, CEO of Wheeler Bio, said in a statement about Wheeler’s first GMP manufacturing in Oklahoma City, “The caliber of collaboration thus far between stakeholders, including Wheeler, CRB and Lingo, has been truly impressive, resulting in a detailed design that is a perfect reflection of our vision of an agile, phase-appropriate ‘smart factory’.”

Illumina opens a new solution center in Dubai

While Dubai may be best known as a tourist destination, one company is trying to bring a broader biotech presence to the city.

DNA sequencing company Illumina has launched a new solution center in Dubai, United Arab Emirates.

The company has established a 9,100 square foot center with a laboratory with a wide range of sequencing and array technologies as well as engineers to provide genomics capabilities to the region. The center will also provide training and education to increase local access to genomics technology and applications

Susan Tousi, Chief Commercial Officer of Illumina, said in a statement:

Illumina opened its UAE-based Solutions Center because we see a tremendous opportunity to deepen our already strong relationships with the country’s ministries of health and technology, as well as science and technology professionals. the health of the region. With a dedicated team representing the entire Illumina ecosystem, we bring more value to our channel partners and customers in the region. We are grateful to the government of the United Arab Emirates for its support and we are honored to partner with the country in its journey towards the age of the genome.

Cell and gene therapy CDMO cuts the ribbon on another New Jersey manufacturing site

BioCentriq, a New Jersey-based cell and gene manufacturer, opened a new manufacturing facility at Princeton Corporate Plaza in South Brunswick, NJ.

According to the company, the addition of two cleanrooms and other infrastructure will help open up more production capacity for BioCentriq and provide more space at its other site in Newark, NJ. The new site will also be able to support manufacturing projects for autologous and allogeneic cell therapies.

The company also plans to expand the site next year with more manufacturing suites, support labs and other infrastructure.

Haro Hartounian, CEO of BioCentriq, said in a statement that additional GMP manufacturing is critical to BioCentriq’s expansion plan, adding “with this additional capacity, BioCentriq can undertake more projects to help biotech companies bring their products from laboratory to market.

Source link


Comments are closed.